Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

Patent metadata

Field	Value
Publication number	US-11701424-B2
Application number	US-202016904511-A
Country	US
Kind code	B2
Filing date	Jun 17, 2020
Priority date	Aug 17, 2016
Publication date	Jul 18, 2023
Grant date	Jul 18, 2023

Abstract

Anti-PVRIG and anti-TIGIT antibodies are provided.

First claim

What is claimed:

1. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-L1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:
i) a heavy chain comprising SEQ ID NO: 9, and
ii) a light chain comprising SEQ ID NO: 14.

2. The method according to claim 1 wherein said T-cells are cytotoxic T-cells (CTLs).

3. The method according to claim 1 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

4. The method according to claim 1 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

5. The method according to claim 1 , wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

6. The method according to claim 5 , wherein the anti-PD-L1 antibody is atezolizumab.

7. The method according to claim 5 , wherein the anti-PD-L1 antibody is avelumab.

8. The method according to claim 5 , wherein the anti-PD-L1 antibody is durvalumab.

9. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-L1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:
i) a heavy chain comprising SEQ ID NO: 19, and
ii) a light chain comprising SEQ ID NO: 24.

10. The method according to claim 1 wherein said T-cells are cytotoxic T-cells (CTLs).

11. The method according to claim 1 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

12. The method according to claim 1 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

13. The method according to claim 1 , wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

14. The method according to claim 13 , wherein the anti-PD-L1 antibody is atezolizumab.

15. The method according to claim 13 , wherein the anti-PD-L1 antibody is avelumab.

16. The method according to claim 13 , wherein the anti-PD-L1 antibody is durvalumab.

17. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:
i) a heavy chain comprising SEQ ID NO: 9, and
ii) a light chain comprising SEQ ID NO: 14.

18. The method according to claim 17 wherein said T-cells are cytotoxic T-cells (CTLs).

19. The method according to claim 17 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

20. The method according to claim 17 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

21. The method according to claim 17 , wherein the anti-PD-1 antibody is selected from the group consisting of pembrolizumab and nivolumab.

22. The method according to claim 21 , wherein the anti-PD-1 antibody is pembrolizumab.

23. The method according to claim 21 , wherein the anti-PD-1 antibody is nivolumab.

24. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:
i) a heavy chain comprising SEQ ID NO: 19, and
ii) a light chain comprising SEQ ID NO: 24.

25. The method according to claim 24 wherein said T-cells are cytotoxic T-cells (CTLs).

26. The method according to claim 24 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

27. The method according to claim 24 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

28. The method according to claim 24 , wherein the anti-PD-1 antibody is selected from the group consisting of pembrolizumab and nivolumab.

29. The method according to claim 28 , wherein the anti-PD-1 antibody is pembrolizumab.

30. The method according to claim 28 , wherein the anti-PD-1 antibody is nivolumab.

Assignees

• Compugen Ltd

Inventors

• White Mark
• Kumar Sandeep
• Chan Christopher
• Liang Spencer
• Stapleton Lance
• Drake Andrew W
• Gozlan Yosi
• Vaknin Ilan
• Sameah-Greenwald Shirley
• Dassa Liat
• Tiran Zohar
• Cojocaru Gad S
• Kotturi Maya
• Cheng Hsin-Yuan
• Hansen Kyle
• Giladi David Nisim
• Safyon Einav
• Ophir Eran
• Presta Leonard
• Theolis Richard
• Desai Radhika
• Wall Patrick

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/39558 Primary

  against tumor tissues, cells, antigens · CPC title

• A61K39/395 Primary

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61K39/39541

  against normal tissues, cells · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title